Updated on 15 July 2015
Tokyo: The National Pharmaceutical Council (NPC) has inducted Takeda Pharmaceuticals USA Inc. (Takeda), a wholly-owned subsidiary of Japanese pharmaceutical major Takeda Pharmaceutical Company Limited, as the newest member of the health care policy research organization.
Located in Deerfield, Illinois, with a global headquarters in Japan, Takeda is a leader in the pharmaceutical industry. Takeda has served communities for more than 230 years through the development of health care solutions from prevention, to care, to cure.
Charles Baum, MD, MS, Vice President, US Medical and Scientific Affairs, will serve as the company's representative on the NPC board of directors.
NPC is actively engaged in conducting health care policy research on understanding the role and value of pharmaceuticals within the current and evolving payment and delivery models, the challenges of individual patient treatment effects and the utilization of real-world evidence and comparative effectiveness research.
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients.